Background Although randomized trials provide a high level of evidence regarding the
efficacy of non-vitamin K oral anticoagulants (NOACs), the results of such trials may differ …

Objective To assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of
stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants …

Background To compare the risk of stroke/systemic embolism (S/SE) and major bleeding
(MB) between non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial …

Background and Purpose—There are limited real-world data comparing the effectiveness
and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians …

Background: Given the huge burden of atrial fibrillation (AF) and AF-related stroke in Asia,
stroke prevention represents an urgent issue in this region. We herein performed a network …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Background and Purpose—Limited evidence exists on the effectiveness and safety of
warfarin and all 4 available non-vitamin K antagonist oral anticoagulants (NOACs) from …

Introduction Non-valvular atrial fibrillation (NVAF) is often accompanied by multiple
comorbid conditions, which increase the associated risks and complexity of patient …

Objective We compared the effectiveness and safety outcomes of non-vitamin K antagonist
oral anticoagulants (NOACs) and warfarin in patients with AF and VHD, as these patients …

The role of non-vitamin K antagonist oral anticoagulants (NOACs) in stroke prevention
remains unclear in Asian patients with atrial fibrillation (AF). Therefore, we performed a meta …